Guard Therapeutics: New strengthening data from AKITA study - Redeye

Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its completed phase IIa study AKITA, which investigated RMC-035 as a renal protective agent during open-heart surgery. Furthermore, the company announced that topline results from the phase IIb study POINTER are anticipated in early November.

Länk till analysen i sin helhet: https://www.redeye.se/research/1129572/guard-therapeutics-new-strengthening-data-from-akita-study?utm_source=finwire&utm_medium=RSS